Accelerating Growth in the Neurovascular Field through the Acquisition of Sequent Medical
First written in FY2016. 8 of 11 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2020-Q3.
No other company in this theme has enough history to compare yet.
- FY2020-Q3AdvancedAnnual report
「In Japan, the TIS (catheter) business, centered on imaging, and Neurovascular products for treating cerebral infarction drove performance. Overseas, WEB, the Neurovascular business's intrasaccular device for treating cerebral aneurysms, was a driver. In addition, the TIS (catheter) business performed well, resulting in a 9.3% year-on-year increase in Cardiovascular Company revenue to ¥263.5 billion.」
WEB and other products related to the neurovascular field following the Sequent Medical acquisition drove overseas sales, and revenue at the Cardiovascular Company increased 9.3% year on year. - FY2020-Q2AdvancedAnnual report
「In Japan, stent grafts for which direct sales began in the Vascular business, and overseas, WEB, the Neurovascular business's intrasaccular device for treating cerebral aneurysms, drove performance. In addition, the global TIS (catheter) business performed well, resulting in a 12.5% year-on-year increase in Cardiovascular Company revenue to ¥172.6 billion.」
WEB, related to the neurovascular field following the Sequent Medical acquisition, drove overseas sales, and revenue at the Cardiovascular Company increased 12.5% year on year. - FY2020-Q1AdvancedAnnual report
「In Japan, stent grafts for which direct sales began in the Vascular business, and overseas, WEB, the Neurovascular business's intrasaccular device for treating cerebral aneurysms, drove performance. In addition, the global TIS (catheter) business performed well, resulting in a 11.3% year-on-year increase in Cardiovascular Company revenue to ¥88.5 billion.」
WEB, related to the neurovascular field following the Sequent Medical acquisition, drove overseas sales, and revenue at the Cardiovascular Company increased 11.3% year on year. - FY2019AdvancedAnnual report
「Development of the WEB, a pouch-shaped embolization device used to treat cerebral aneurysms, progressed, and marketing approval was obtained in the United States in December 2018.」
Following the Sequent Medical acquisition, marketing approval for WEB was obtained in the United States in the neurovascular field. The disclosure also stated that approval was obtained in Japan for the SOFIAFLOW Plus aspiration catheter for cerebral thrombus removal. - FY2019-Q2AdvancedAnnual report
「Revenue increased as the neurovascular business of the Cardiovascular Company and the alliance business of the Hospital Company performed well, while products for blood centers from the Blood Management Company also drove growth.」
Following the Sequent Medical acquisition, the neurovascular business performed well and contributed to higher overseas sales. - FY2019-Q1AdvancedAnnual report
「Overseas, in addition to access products and oncology products in the TIS business, hydrogel-based coils for the treatment of cerebral aneurysms and aspiration catheters in the neurovascular business drove growth.」
Following the Sequent Medical acquisition, coils for the treatment of cerebral aneurysms and aspiration catheters drove overseas sales in the neurovascular field. - FY2018AdvancedAnnual report
「Sales of hydrogel-based coils for the treatment of cerebral aneurysms and aspiration catheters performed well in the neurovascular business.」
Following the Sequent Medical acquisition, sales of coils for the treatment of cerebral aneurysms and aspiration catheters performed well in the neurovascular field. - FY2017-Q3AdvancedAnnual report
「The accounting for the business combination with Sequent Medical, Inc. on 14 July 2016 was provisional during the second quarter of the consolidated fiscal year, but was finalized during the third quarter.」
The provisional purchase accounting for the Sequent Medical acquisition was finalized in the third quarter. - FY2017-Q2RestatedAnnual report
「Business combination date 14 July 2016 Voting rights acquired 100%」
The business combination note confirmed 14 July 2016 as the business combination date for Sequent Medical, Inc. and a 100% voting interest. - FY2017-Q1AchievedAnnual report
「Terumo Americas Holding, Inc. acquired all shares of Sequent Medical, Inc. of California, USA, on 13 July 2016. Sequent Medical had developed and commercialized a novel-shaped embolization device for the treatment of cerebral aneurysms, the first such product in the world. The acquisition is referred to below as the “Acquisition.”」
All shares of Sequent Medical were acquired on 13 July 2016, completing the acquisition process. The post-acquisition ownership interest was 100%. - FY2016First statedAnnual report
「Neurovascular treatment through this acquisition is a priority field alongside catheter-based treatment, and the acquisition will accelerate growth across the Group.」
An agreement to acquire all shares was signed on 12 June 2016. The consideration comprised an upfront payment of US$280 million and milestone payments of up to US$100 million contingent on the achievement of specified conditions. The acquisition was expected to close between July and August 2016.